We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zimmer Biomet (ZBH) Q2 Earnings Top Estimates, 2022 View Up
Read MoreHide Full Article
Zimmer Biomet Holdings, Inc. (ZBH - Free Report) posted second-quarter 2022 adjusted earnings per share (EPS) of $1.82, beating the Zacks Consensus Estimate by 11.7%. The adjusted figure also rose a significant 20.5% year over year.
The quarter’s adjustments included certain amortization, restructuring and quality remediation-related charges, among others.
On a reported basis, the company registered earnings of 73 cents per share, a 7.4% rise from earnings a year ago.
Revenue Details
Second-quarter net sales of $1.78 billion increased 1% (up 6% at constant exchange rate or CER) year over year. The figure beat the Zacks Consensus Estimate by 3.5%.
Geographic Details
Zimmer Biomet updated its geographic sales reporting with two segments: United States and International.
During the second quarter, sales generated in the United States totaled $1.02 billion (up 1.3% year over year at CER) while the same in International grossed $764 million (up 12.2% year over year at CER).
Segments
In terms of product categories, post the dental and spine arm sell-off, the company continues to report through the remaining four product categories.
Sales in the Knees unit improved 11.2% year over year at CER to $704.9 million. Hips recorded an 8.6% rise at CER to $487.2 million. Revenues in the S.E.T. (Sports Medicine, Extremities, Trauma, Craniomaxillofacial and Thoracic) unit increased 0.1% year over year to $446.4 million.
Zimmer Biomet Holdings, Inc. Price, Consensus and EPS Surprise
Earlier the company noted that its CMFT (Craniomaxillofacial and Thoracic) products, previously reported in the Dental, Spine & CMFT category, are now included in the S.E.T. category.
Margins
Gross margin, after excluding intangible asset amortization, was 71.3%, reflecting a contraction of 54 basis points (bps) in the second quarter. Selling, general and administrative expenses were down 0.2% to $695.2 million. Research and development expenses rose 39.8% to $99.4 million. Adjusted operating margin expanded 374 bps to 26.7% in the quarter.
Cash Position
Zimmer Biomet exited the second quarter of 2022 with cash and cash equivalents of $386.4 million compared with $435.8 million at the end of the first quarter of 2022.
Cumulative net cash provided by operating activities at the end of the second quarter was $661.2 million compared with $642.5 million in the year-ago period.
2022 Guidance
Zimmer Biomet updated its financial guidance for 2022.
Revenues are expected to be down 1% to up 1% (an improvement from the earlier band of down 1.5% to up 0.5%) compared with 2021.
Adjusted EPS for the full year is expected in the range of $6.70-$6.90 (a rise from the projection of $6.65-$6.85 earlier).
The Zacks Consensus Estimate for 2022 adjusted earnings is pegged at $6.80 on revenues of $6.69 billion.
Our Take
Zimmer Biomet ended the second quarter of 2022 with better-than-expected earnings and revenues. Each of the company’s geographic segments and product divisions barring “other” recorded year-over-year sales growth at CER. A raised 2022 guidance is indicative of this improving trend to continue for the rest of the year. However, a contraction in the company’s gross margins is concerning. A significant reduction in R&D expenses too increases concern about pipeline-related progress.
Zacks Rank and Key Picks
Zimmer Biomet currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space that have announced quarterly results are Quest Diagnostics Incorporated (DGX - Free Report) , Humana Inc. (HUM - Free Report) and Alkermes plc (ALKS - Free Report) .
Quest Diagnostics, carrying a Zacks Rank #2 (Buy), reported second-quarter 2022 adjusted EPS of $2.36, which beat the Zacks Consensus Estimate by 9.8%. Revenues of $2.45 billion outpaced the consensus mark by 7.5%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Quest Diagnostics has an earnings yield of 7.1% compared with the industry’s 3.3%. DGX’s earnings surpassed estimates in three of the trailing four quarters and missed the same in one, the average being 12.1%.
Humana, having a Zacks Rank #2, reported second-quarter 2022 adjusted EPS of $8.67, which beat the Zacks Consensus Estimate by 13%. Revenues of $23.7 billion outpaced the consensus mark by 1.2%.
Humana has an estimated long-term growth rate of 13.5%. HUM’s earnings surpassed estimates in all the trailing four quarters, the average being 9.1%.
Alkermes reported second-quarter 2022 adjusted EPS of 6 cents, which surpassed the Zacks Consensus Estimate by 50%. Second-quarter revenues of $276.2 million outpaced the Zacks Consensus Estimate by 1.1%. It currently has a Zacks Rank #2.
Alkermes has an estimated long-term growth rate of 24.9%. ALKS’s earnings surpassed estimates in all the trailing four quarters, the average being 325.5%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Zimmer Biomet (ZBH) Q2 Earnings Top Estimates, 2022 View Up
Zimmer Biomet Holdings, Inc. (ZBH - Free Report) posted second-quarter 2022 adjusted earnings per share (EPS) of $1.82, beating the Zacks Consensus Estimate by 11.7%. The adjusted figure also rose a significant 20.5% year over year.
The quarter’s adjustments included certain amortization, restructuring and quality remediation-related charges, among others.
On a reported basis, the company registered earnings of 73 cents per share, a 7.4% rise from earnings a year ago.
Revenue Details
Second-quarter net sales of $1.78 billion increased 1% (up 6% at constant exchange rate or CER) year over year. The figure beat the Zacks Consensus Estimate by 3.5%.
Geographic Details
Zimmer Biomet updated its geographic sales reporting with two segments: United States and International.
During the second quarter, sales generated in the United States totaled $1.02 billion (up 1.3% year over year at CER) while the same in International grossed $764 million (up 12.2% year over year at CER).
Segments
In terms of product categories, post the dental and spine arm sell-off, the company continues to report through the remaining four product categories.
Sales in the Knees unit improved 11.2% year over year at CER to $704.9 million. Hips recorded an 8.6% rise at CER to $487.2 million. Revenues in the S.E.T. (Sports Medicine, Extremities, Trauma, Craniomaxillofacial and Thoracic) unit increased 0.1% year over year to $446.4 million.
Zimmer Biomet Holdings, Inc. Price, Consensus and EPS Surprise
Zimmer Biomet Holdings, Inc. price-consensus-eps-surprise-chart | Zimmer Biomet Holdings, Inc. Quote
Other revenues fell 6.1% to $143.3 million.
Earlier the company noted that its CMFT (Craniomaxillofacial and Thoracic) products, previously reported in the Dental, Spine & CMFT category, are now included in the S.E.T. category.
Margins
Gross margin, after excluding intangible asset amortization, was 71.3%, reflecting a contraction of 54 basis points (bps) in the second quarter. Selling, general and administrative expenses were down 0.2% to $695.2 million. Research and development expenses rose 39.8% to $99.4 million. Adjusted operating margin expanded 374 bps to 26.7% in the quarter.
Cash Position
Zimmer Biomet exited the second quarter of 2022 with cash and cash equivalents of $386.4 million compared with $435.8 million at the end of the first quarter of 2022.
Cumulative net cash provided by operating activities at the end of the second quarter was $661.2 million compared with $642.5 million in the year-ago period.
2022 Guidance
Zimmer Biomet updated its financial guidance for 2022.
Revenues are expected to be down 1% to up 1% (an improvement from the earlier band of down 1.5% to up 0.5%) compared with 2021.
Adjusted EPS for the full year is expected in the range of $6.70-$6.90 (a rise from the projection of $6.65-$6.85 earlier).
The Zacks Consensus Estimate for 2022 adjusted earnings is pegged at $6.80 on revenues of $6.69 billion.
Our Take
Zimmer Biomet ended the second quarter of 2022 with better-than-expected earnings and revenues. Each of the company’s geographic segments and product divisions barring “other” recorded year-over-year sales growth at CER. A raised 2022 guidance is indicative of this improving trend to continue for the rest of the year. However, a contraction in the company’s gross margins is concerning. A significant reduction in R&D expenses too increases concern about pipeline-related progress.
Zacks Rank and Key Picks
Zimmer Biomet currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space that have announced quarterly results are Quest Diagnostics Incorporated (DGX - Free Report) , Humana Inc. (HUM - Free Report) and Alkermes plc (ALKS - Free Report) .
Quest Diagnostics, carrying a Zacks Rank #2 (Buy), reported second-quarter 2022 adjusted EPS of $2.36, which beat the Zacks Consensus Estimate by 9.8%. Revenues of $2.45 billion outpaced the consensus mark by 7.5%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Quest Diagnostics has an earnings yield of 7.1% compared with the industry’s 3.3%. DGX’s earnings surpassed estimates in three of the trailing four quarters and missed the same in one, the average being 12.1%.
Humana, having a Zacks Rank #2, reported second-quarter 2022 adjusted EPS of $8.67, which beat the Zacks Consensus Estimate by 13%. Revenues of $23.7 billion outpaced the consensus mark by 1.2%.
Humana has an estimated long-term growth rate of 13.5%. HUM’s earnings surpassed estimates in all the trailing four quarters, the average being 9.1%.
Alkermes reported second-quarter 2022 adjusted EPS of 6 cents, which surpassed the Zacks Consensus Estimate by 50%. Second-quarter revenues of $276.2 million outpaced the Zacks Consensus Estimate by 1.1%. It currently has a Zacks Rank #2.
Alkermes has an estimated long-term growth rate of 24.9%. ALKS’s earnings surpassed estimates in all the trailing four quarters, the average being 325.5%.